{"content":[{"text":"May 6, 2021","bbox":{"left":0.098039,"top":0.06867,"width":0.10825499999999998,"height":0.016926999999999998}},{"text":"Syros Reports First Quarter 2021 Financial \n Results and Highlights Key \n Accomplishments and Upcoming \n Milestones","bbox":{"left":0.098039,"top":0.133552,"width":0.795496,"height":0.13896799999999998}},{"text":"Enrolling Patients in Phase 3 Trial of SY-1425 in Combination with Azacitidine in RARA- \n Positive Newly Diagnosed Higher-Risk MDS Patients","bbox":{"left":0.119485,"top":0.294049,"width":0.761144,"height":0.03491900000000003}},{"text":"Today Announced Three-Part KOL Webinar Series on Its Portfolio of Investigational \n Targeted Hematology Therapies, Beginning May 2021","bbox":{"left":0.137255,"top":0.345185,"width":0.72527,"height":0.03492000000000001}},{"text":"On Track to Achieve 2021 Milestones, Including Initiation of SY-1425 and SY-2101 Clinical \n Trials in 2H 2021 and Additional Dose-Escalation Data for SY-5609 in 3Q 2021","bbox":{"left":0.10723,"top":0.396322,"width":0.7851659999999999,"height":0.03491900000000003}},{"text":"Management to Host Conference Call at 8:30 a.m. ET Today","bbox":{"left":0.239583,"top":0.447458,"width":0.527038,"height":0.016927000000000025}},{"text":"CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Syros Pharmaceuticals (NASDAQ:SYRS), a \n leader in the development of medicines that control the expression of genes, today reported \n financial results for the quarter ended March 31, 2021, and provided an update on recent \n accomplishments and upcoming events.","bbox":{"left":0.098039,"top":0.480602,"width":0.793898,"height":0.07090400000000008}},{"text":"“We continue to make substantial progress toward our vision of building Syros into a fully \n integrated company, with leading portfolios in targeted hematology and selective CDK \n inhibition and a robust gene control discovery engine,” said Nancy Simonian, M.D., Chief \n Executive Officer of Syros. “We began enrolling patients in our Phase 3 clinical trial of SY- \n 1425 in RARA-positive higher-risk MDS, marking the start of our first registration-enabling \n trial and an important step toward our goal of setting new standards of care in the treatment \n of hematologic malignancies. Looking ahead, we are poised to continue building on this \n momentum. We look forward to initiating additional clinical trials with SY-1425 and SY-2101 \n in the second half of the year and reporting new dose-escalation data, including clinical \n activity, from our Phase 1 trial of SY-5609 in the third quarter, while continuing to invest in \n our earlier-stage programs in cancer and monogenic diseases.”","bbox":{"left":0.098039,"top":0.567723,"width":0.791638,"height":0.196851}},{"text":"Syros today announced plans to host a three-part KOL webinar series focused on its \n portfolio of investigational targeted hematology therapies. This series will consist of \n presentations from key opinion leaders and clinical collaborators who will review the unmet \n need and evolving landscapes in higher-risk myelodysplastic syndrome (HR-MDS), newly \n diagnosed unfit acute myeloid leukemia (AML), and acute promyelocytic leukemia (APL), as \n well as Syros leaders who will review recent progress for SY-1425 and for SY-2101 in these \n diseases. Each event will be webcast live on the Investors & Media section of Syros’ \n website, www.syros.com. More details for the series are forthcoming.","bbox":{"left":0.098039,"top":0.780791,"width":0.794979,"height":0.14287400000000006}}],"images_bbox":[{"left":0.656863,"top":0.068182,"width":0.245098,"height":0.045455}],"images_bbox_not_text_overlap":[{"left":0.656863,"top":0.068182,"width":0.245098,"height":0.045455}]}